New research finds GLP-1 users are judged more harshly than dieters, and sometimes more than people who haven't lost weight. Here's what the study shows.

Phase 3 trial: survodutide produced up to 16.6% weight loss in 76 weeks. How it compares to Mounjaro, Wegovy, and Wegovy 7.2 mg.

A new MRI study of 615 adults found higher ultra-processed food intake was linked to more fat stored inside muscle tissue, even when calories were matched.

A Nature study of 27,885 people identified gene variants that predict GLP-1 weight loss and nausea risk, including one specific to Mounjaro users.

The FDA has approved Foundayo (orforglipron), a daily GLP-1 pill for weight loss with no fasting requirements. Average weight loss of 11.2% at 72 weeks.

The OASIS 4 trial found oral semaglutide 25 mg produced 13.6% weight loss over 64 weeks, comparable to injectable Wegovy. UK approval expected late 2026.

Mayo Clinic research found 4 obesity phenotypes that drive weight gain differently. When treatment matched a person's phenotype, weight loss nearly doubled.

A study of 8,000 patients found weight regain after stopping GLP-1 medications was far less than clinical trials predicted. Here's why.

Second Nature combines Mounjaro & Wegovy weight-loss medications with support from registered dietitians. NHS-used since 2017, with ~18-22% weight loss.

Second Nature's medication weight-loss programme will now be available to Vitality members. It combines weight-loss injections with habit change support.